Arbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 2.83%

June 16, 2018 - By Nellie Frank

Arbutus Biopharma Corporation (NASDAQ:ABUS) Logo

The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) registered a decrease of 2.83% in short interest. ABUS’s total short interest was 692,500 shares in June as published by FINRA. Its down 2.83% from 712,700 shares, reported previously. With 152,800 shares average volume, it will take short sellers 5 days to cover their ABUS’s short positions. The short interest to Arbutus Biopharma Corporation’s float is 2.3%.

The stock increased 5.83% or $0.35 during the last trading session, reaching $6.35. About 579,130 shares traded or 223.53% up from the average. Arbutus Biopharma Corporation (NASDAQ:ABUS) has risen 64.29% since June 16, 2017 and is uptrending. It has outperformed by 51.72% the S&P500.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $350.32 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

More recent Arbutus Biopharma Corporation (NASDAQ:ABUS) news were published by: which released: “Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer” on June 07, 2018. Also published the news titled: “Arbutus Biopharma (ABUS) Announces Appointment of David C. Hastings as New Chief Financial Officer” on June 07, 2018.‘s news article titled: “Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with …” with publication date: June 06, 2018 was also an interesting one.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: